Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 16/20 | 0.47 |
| ▸ | FNTB | P49356 | 16/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | RORB | Q92753 | 1/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | BAD | Q92934 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6971909 | 0.91 | FNTA (0.52) | FNTAFNTBRORCRORBPGGT1B | |
| SCHEMBL6976425 | 0.88 | FNTA (0.56) | FNTAFNTBCNR2 | |
| SCHEMBL6984623 | 0.86 | FNTA (0.56) | FNTAFNTBCNR2 | |
| SCHEMBL6975762 | 0.84 | FNTA (0.66) | FNTAFNTBPGGT1BCYP3A4CNR2 | |
| SCHEMBL6973254 | 0.84 | FNTA (0.47) | FNTAFNTBPGGT1BCYP3A4CNR2 | |
| SCHEMBL6979313 | 0.83 | FNTA (0.52) | FNTAFNTBMCL1BADPGGT1B | |
| SCHEMBL6982646 | 0.83 | FNTA (0.67) | FNTAFNTBPGGT1BCYP3A4CNR2 | |
| SCHEMBL6925142 | 0.82 | FNTA (0.53) | FNTAFNTBMCL1BADALDH1A1 | |
| SCHEMBL6976044 | 0.81 | FNTA (0.56) | FNTAFNTBALDH1A1PGGT1BCYP3A4 | |
| SCHEMBL6981333 | 0.81 | FNTA (0.59) | FNTAFNTBCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1045846-B1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD (KR) | 2003-05-02 | — | — | EP | claimed |
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | LG CHEMICAL LTD. | 2002-09-26 | — | — | US | claimed |
| US-6268363-B1 | ANTITUMOR | LG CHEMICAL LTD. (KR) | 2001-07-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | FNTA, FNTB, FDPS | FNTA 1/4885FNTB 2/4885RORC 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.